Updated October 2026
Introduction
Australia’s therapeutic vaping framework establishes strict regulatory requirements for electronic cigarettes, vaping liquids, devices, and associated accessories.
For manufacturers, sponsors, importers, and healthcare-sector distributors, understanding Australia therapeutic vape standards is essential when evaluating product compliance.
The Therapeutic Goods Administration (TGA) regulates therapeutic vaping goods intended for smoking cessation or the management of nicotine dependence. Australia’s framework differs considerably from markets where recreational vaping products are distributed through ordinary retail stores.
Strengthened product standards introduced during 2025 increased requirements relating to permitted ingredients, nicotine concentration, packaging, labelling, product traceability, and device safety.
These standards are particularly important for businesses that manufacture therapeutic vaping substances or devices outside Australia.
This article explains the key provisions of TGO 110, the standards applicable to therapeutic vaping devices, sponsor compliance responsibilities, and the country’s pharmacy-based supply framework.
1. What Are Therapeutic Vapes in Australia?
Therapeutic vapes are vaping products intended for smoking cessation or the management of nicotine dependence.
They may include vaping substances, refillable devices, cartridges, pods, and accessories that meet applicable requirements.
In Australia, recreational vaping products cannot be legally supplied through ordinary commercial retail channels.
Therapeutic Vapes vs. Recreational Vapes
The distinction is primarily regulatory rather than simply technological.
A vaping device being refillable, rechargeable, or marketed with clinical-looking packaging does not automatically make it eligible for therapeutic supply.
Relevant considerations include the product’s intended use, applicable standards, import permissions, regulatory notifications, and permitted supply channels.
Who Regulates Therapeutic Vaping Products?
The Therapeutic Goods Administration, part of Australia’s Department of Health, Disability and Ageing, administers key federal therapeutic vaping requirements.
State and territory laws also influence pharmacy supply and consumer access.
2. Understanding TGO 110
The Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021, as amended, establishes requirements for relevant therapeutic vaping substances and associated goods.
Strengthened requirements began applying during 2025.
TGO 110 addresses several important areas:
- Permitted ingredients and formulation requirements.
- Nicotine concentration and declared content.
- Restricted and prohibited substances.
- Flavour limitations.
- Containers and child-resistant packaging.
- Product presentation and labelling.
- Consumer information leaflets.
- Product identification and traceability.
The requirements should be read together with the applicable legislation and guidance concerning therapeutic vaping devices.
Why Does TGO 110 Matter?
A product’s appearance, nicotine content, or popularity in international markets does not demonstrate compliance.
For therapeutic vaping substances, regulatory conformity requires consideration of the complete formulation and relevant product specifications.
This means that changing a product label or reducing nicotine concentration may not be sufficient to make an otherwise non-compliant product eligible for supply.
3. Permitted Ingredients in Australian Therapeutic Vaping Liquids
Australia has established a restricted formulation framework for therapeutic vaping substances.
The strengthened TGO 110 requirements identify permitted ingredients, including:
- Nicotine.
- Propylene glycol.
- Glycerol.
- Water.
- Permitted mint, menthol, or tobacco flavouring ingredients.
Other ingredients cannot simply be added on the assumption that they are acceptable in conventional consumer vaping liquids.
Restrictions on Flavouring Ingredients
Permitted flavouring components are subject to additional requirements.
Flavouring substances should be necessary for the relevant flavour or its stability and must not include prohibited ingredients.
The TGA also restricts the use of certain substances associated with inhalation risks.
Importantly, a product described as mint, tobacco, or menthol flavoured is not automatically compliant: its actual ingredient composition must also meet the relevant standards.
Why Ingredient Verification Matters
Product sponsors and manufacturers should ensure that formulation records support the identity and quantities of the ingredients present.
Appropriate documentation may include ingredient specifications, relevant analytical results, and manufacturing quality records.
Ingredient compliance must be assessed against the applicable requirements rather than relying only on marketing descriptions.
4. Nicotine Concentration Requirements
Nicotine concentration is an important component of Australia’s therapeutic vaping standards.
Under the strengthened TGO 110 framework, therapeutic vaping substances are subject to a maximum nicotine concentration of 50 mg/mL.
Actual nicotine content must also be consistent with the declared amount, within the specified tolerance.
The TGA’s guidance identifies an acceptable range of 90% to 110% of the stated nicotine content.
Product Standards vs. Patient Access Rules
Manufacturers and distributors should distinguish between the maximum nicotine concentration permitted under product standards and the requirements governing pharmacy supply.
For example, eligible adults may obtain certain therapeutic vapes containing 20 mg/mL nicotine or less from participating pharmacies without a prescription, subject to pharmacist assessment and applicable local law.
Higher concentrations generally require a prescription.
A product meeting the manufacturing concentration limit therefore does not automatically qualify for non-prescription supply.
5. Therapeutic Vape Packaging Requirements
Australia’s strengthened therapeutic vaping framework includes plain-packaging and pharmaceutical-style presentation requirements.
These standards are designed to provide appropriate product information and reduce the potential appeal of vaping products to young people.
Plain Packaging
Therapeutic vaping products must comply with applicable restrictions on packaging appearance and product names.
Packaging used for recreational vaping products in overseas markets may not meet Australian requirements.
Labelling Information
Depending on the product and packaging type, relevant labelling requirements may address:
- Product identification.
- Nicotine concentration or content.
- Permitted flavour identification.
- Liquid volume.
- Required warning statements.
- Batch or traceability information.
- Applicable manufacturer or sponsor details.
Businesses must check which requirements apply to the container, primary packaging, and any additional packaging layers.
Information Leaflets
TGO 110 also includes requirements relating to patient information.
Therapeutic vaping goods may need an information leaflet or compliant instructions for accessing the information electronically.
The information must be understandable and meet the applicable content requirements.
6. Device Safety Standards for Therapeutic Vapes
Therapeutic vaping devices are subject to requirements that extend beyond the chemical composition of e-liquids.
Australia’s enhanced medical device standards address several technical safety considerations.
Battery and Electrical Safety
Battery-powered vaping devices can present risks associated with electrical faults, overheating, and improper charging.
Applicable device standards address battery and electrical safety requirements as part of the broader regulatory framework.
Device Design and Construction
Relevant requirements may also concern the design, construction, quality, and risk management of therapeutic vaping devices.
These provisions are particularly important because therapeutic devices are intended to be supplied within a healthcare-focused regulatory environment.
Toxicological Risk Assessment
The applicable framework includes toxicological risk considerations relating to device materials and potential exposure during intended use.
Product conformity therefore involves more than external appearance or basic operational testing.
Manufacturers and sponsors should consult the detailed medical device standard and TGA guidance applicable to their particular products.
7. Sponsor Responsibilities and Product Notifications
A company responsible for placing therapeutic vaping goods into the Australian market may have regulatory obligations as the product sponsor.
For relevant unapproved therapeutic vaping goods, the TGA requires sponsors to notify it of compliance with the applicable product standards before importation or supply.
Does a Sponsor Notification Mean TGA Approval?
No.
A sponsor notification does not necessarily mean that the TGA has individually evaluated or approved the product’s safety, quality, or effectiveness.
The TGA cautions that even products compliant with the applicable standards may have uncertain long-term risks.
Documentation and Traceability
Sponsors should maintain records sufficient to substantiate compliance with relevant standards.
Depending on the goods and legal obligations, these may include formulation information, product specifications, safety documentation, manufacturing records, and traceability information.
Businesses should verify notification and recordkeeping obligations before undertaking commercial activities.
8. Pharmacy Supply Requirements
Australia’s lawful retail supply of therapeutic vaping products is restricted to participating pharmacies.
This framework applies to relevant therapeutic vaping goods, including nicotine-free products.
Adult Access
For adults aged 18 years or over, certain therapeutic vapes containing no more than 20 mg/mL of nicotine may be supplied without a prescription under applicable federal and state or territory rules.
The pharmacist must determine whether supply is clinically appropriate and meet the relevant professional and regulatory requirements.
Prescription Requirements
Prescriptions remain necessary in several circumstances, including supply of therapeutic vapes containing more than 20 mg/mL of nicotine.
People under 18 also generally require a prescription where local laws permit access.
Business Implications
The pharmacy-based system means that ordinary convenience stores, petrol stations, tobacconists, and recreational vape shops are not lawful consumer retail channels.
Regulatory compliance must therefore cover both the product and the proposed supply chain.
9. Therapeutic Vape Compliance Checklist
The following table summarizes important regulatory considerations for businesses researching Australia’s therapeutic vaping framework.
| Compliance Area | Key Consideration |
|---|---|
| Product classification | Determine applicable therapeutic vaping requirements |
| Ingredient formulation | Verify permitted ingredients and prohibited substances |
| Nicotine content | Check maximum concentration and declared-content accuracy |
| Flavours | Confirm compliance with mint, menthol, or tobacco restrictions |
| Packaging | Meet applicable plain-packaging requirements |
| Labelling | Provide required statements and product information |
| Information leaflets | Meet applicable patient-information requirements |
| Device standards | Assess electrical, battery, construction, and safety requirements |
| Sponsor notification | Complete required regulatory notification |
| Importation | Obtain applicable import licences and permissions |
| Distribution | Supply only through legally permitted arrangements |
A compliance review should be tailored to the exact product rather than applying a generic checklist without further assessment.
10. Why International Product Standards Are Not Enough
Manufacturers supplying multiple international markets may use common production platforms, components, and quality systems.
However, compliance with foreign regulations does not automatically establish conformity with Australian law.
A product meeting another country’s electronic cigarette rules may still fail Australia’s therapeutic vaping requirements because of its ingredients, flavour, packaging, intended use, or device specifications.
Businesses should therefore avoid treating international certifications as substitutes for Australian regulatory assessment.
Frequently Asked Questions
1. What is TGO 110 in Australia?
TGO 110 is a therapeutic goods standard governing relevant therapeutic vaping substances and associated products. It addresses ingredients, nicotine content, containers, labelling, and other product requirements.
2. What is the maximum nicotine concentration for therapeutic vapes in Australia?
The strengthened product standard generally limits therapeutic vaping substances to 50 mg/mL nicotine. Separate prescribing and pharmacy supply rules apply at concentrations above 20 mg/mL.
3. What flavours are permitted for therapeutic vapes?
The permitted categories are tobacco, mint, and menthol. The ingredients used to produce these flavours must also comply with the relevant formulation requirements.
4. Do therapeutic vaping devices have battery safety requirements?
Yes. Applicable medical device standards address battery and electrical safety alongside device construction, risk management, and other technical requirements.
5. Does a TGA sponsor notification mean a vape is approved?
No. Sponsor notification of standards compliance should not be confused with individual TGA evaluation or approval of the product’s safety and effectiveness.
6. Can therapeutic vapes be sold outside pharmacies?
Australia restricts lawful retail supply to participating pharmacies, subject to the relevant regulatory and clinical requirements.
7. Are nicotine-free therapeutic vapes regulated?
Yes. Australia’s vaping framework also covers relevant nicotine-free vaping products. The absence of nicotine does not remove the applicable regulatory obligations.
8. Can manufacturers use the same packaging as in other countries?
Not automatically. Australia’s requirements include specific restrictions on product presentation, labelling, warnings, and consumer information.
Conclusion
Australia’s therapeutic vaping standards establish a detailed framework covering formulation, nicotine concentration, packaging, labelling, device safety, and regulated pharmacy supply.
The strengthened TGO 110 requirements and applicable medical device standards place significant responsibilities on manufacturers, sponsors, and importers.
For businesses examining this sector, understanding both product standards and distribution restrictions is essential.
The most reliable approach is to review the applicable legislation and current TGA guidance for the exact products concerned, supported by qualified regulatory advice.
Disclaimer: This article provides general regulatory and industry information and is not legal, medical, or commercial import advice. Requirements may change and should be checked against current Australian legislation.
https://www.legislation.gov.au/F2021L00595/latest?utm_source=chatgpt.com